TSXV:TRL.H - Post by User
Comment by
LTOWNERon Jul 11, 2012 11:15am
219 Views
Post# 20102102
RE: Share price and Compleo Trials
RE: Share price and Compleo Trials No, it could not be! This Trial is nowhere near completion, let alone failing. Statistically speaking it is highly unlikely that the very positive results seen in the preliminary review of the Compleo Phase III trial will not be duplicated or exceeded in the final results. "The preliminary data was obtained from 139 hypogonadal patients who had completed 30 days treatment and laboratory analysis ... review of early data demonstrated that 79.9 per cent of patients treated with CompleoTRT achieved an average serum testosterone (AST) level within the normal range. These results exceed the threshold required by the U.S. Food and Drug Administration (FDA) to confirm the efficacy of a testosterone replacement product." Obviously the intra-nasal delivery system works and it works with a testosterone dose lower than that of all competitors. The full trial period is 90 days for each patient, including those just recruited and beginning the trial at the end of June.
This information also bodes well for the Tefina study, at least in so far as the intra-nasal delivery system's ability to facilitate uptake of a minute quantity of testosterone in females.